Ciforadenant
As of the edition of 20 October 2026, Ciforadenant is a small molecule: stopped in 2025; acts on ADORA2A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 8, 1 stopped early
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Ciforadenant.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADORA2A | Adenosine receptor A2a | P29274 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 3 | 1 | 1 | 1 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Vernalis | Lead sponsor of trials | 2011 to now |
| Corvus Pharmaceuticals | Lead sponsor of trials | 2016 to now |
| Roche | Lead sponsor of trials | 2017 to now |